Cited by 127Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase SignalingHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Afatinib restrains K-RAS–driven lung tumorigenesis

Open access

Moll, Herwig P., Pranz, Klemens, Musteanu, Monica, Grabner, Beatrice, Hruschka, Natascha, Mohrherr, Julian, Aigner, Petra, Stiedl, Patricia, Brcic, Luka, Laszlo, Viktoria, Schramek, Daniel, Moriggl, Richard, Eferl, Robert, Moldvay, Judit, Dezso, Katalin, Lopez-Casas, Pedro P., Stoiber, Dagmar, Hidalgo, Manuel, Penninger, Josef, Sibilia, Maria, Győrffy, Balázs, Barbacid, Mariano, Dome, Balázs, Popper, Helmut, Casanova, Emilio·2018·Science Translational Medicine

DOI 10.1126/scitranslmed.aao2301PMC PMC7610658

Open this paper in CoChat — free account

Abstract

K-RAS –mutated lung adenocarcinomas depend on ERBB signaling, and pan-ERBB inhibitors impair K-RAS–driven lung tumorigenesis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aao2301

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
Cancer statistics, 2016
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper – Excel-based tool using pair-wise correlations
Pfaffl, M. W., Tichopad, A., Prgomet, C., & Neuvians, T. P. (2004) · Biotechnology Letters · doi:10.1023/b:bile.0000019559.84305.47 · Cited by 5,065
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Show all 51 references

Sorted by citations

RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Inflammatory Signals Induce AT2 Cell-Derived Damage-Associated Transient Progenitors that Mediate Alveolar Regeneration
Choi, J., Park, J.-E., Tsagkogeorga, G., Yanagita, M., Koo, B., Han, N., & Lee, J. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.06.020 · Cited by 580
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
“Previous studies have suggested that key RTKs may play dominant roles in driving adaptive feedback to inhibitors of the MAPK pathway, including EGFR in response to BRAF inhibition in BRAF colorectal cancer and EGFR/HER family kinases or FGFR in response to MEK inhibitors in KRAS-mutant lung cancers (13, 14, 21, 24).”
Background
BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0142 · Cited by 444
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 209
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Santoni‐Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 202
Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma
Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0620 · Cited by 182
KRAS G12C inhibition produces a driver-limited state revealing collateral dependencies
Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw9450 · Cited by 175
Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling
Ponsioen, B., Post, J. B., Amorie, J. R. B. D., Laskaris, D., van Ineveld, R. L., Kersten, S., Bertotti, A., Sassi, F. P., Sipieter, F., Cappe, B., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00654-5 · Cited by 148
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges
Xiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366260 · Cited by 152
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 138
Self-citation
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129
TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target
Yu, J., Zhou, D., Yang, X., Cui, B., Tan, F., Wang, J., Li, K., Shang, S., Zhang, C., Lv, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17385-0 · Cited by 116
The ERBB network facilitates KRAS-driven lung tumorigenesis
Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, S., Coffelt, S. B., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2565 · Cited by 111
High expression levels of pyrimidine metabolic rate–limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on The Cancer Genome Atlas and Gene Expression Omnibus datasets
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2020) · Purinergic Signalling · doi:10.1007/s11302-020-09711-4 · Cited by 104
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer
Gong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92
Prevalence and role of HER2 mutations in cancer
Cocco, E., Lopez, S., Santin, A. D., & Scaltriti, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.010 · Cited by 89
Predicting and characterizing a cancer dependency map of tumors with deep learning
Chiu, Y.-C., Zheng, S., Wang, L.-J., Iskra, B. S., Rao, M. K., Houghton, P. J., Huang, Y., & Chen, Y. (2021) · Science Advances · doi:10.1126/sciadv.abh1275 · Cited by 84
“Thus, a pan-ERBB inhibitor, afatinib, effectively inhibited tumor growth of KRAS-mutated NSCLC on patient- or cell line– derived xenografts (44).”
Background
Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells
Dent, P., Booth, L. A., Roberts, J. L., Liu, J., Poklepovic, A. S., Lalani, A. S., Tuveson, D. A., Martinez, J., & Hancock, J. F. (2019) · Oncogene · doi:10.1038/s41388-019-0849-8 · Cited by 80
Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)—development and in-vitro efficacy
Elbatanony, R. S., Parvathaneni, V., Kulkarni, N. S., Shukla, S. K., Chauhan, G., Kunda, N. K., & Gupta, V. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00802-8 · Cited by 84
KRAS in NSCLC: State of the Art and Future Perspectives
Cascetta, P., Marinello, A., Lazzari, C., Gregorc, V., Planchard, D., Bianco, R., Normanno, N., & Morabito, A. (2022) · Cancers · doi:10.3390/cancers14215430 · Cited by 76
Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients
Chen, J., Chu, X., Zhang, J., Nie, Q., Tang, W., Su, J., Yan, H., Zheng, H., Chen, Z., Chen, X., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13542 · Cited by 78
JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression
Mohrherr, J., Haber, M., Breitenecker, K., Aigner, P., Moritsch, S., Voronin, V., Eferl, R., Moriggl, R., Stoiber, D., Győrffy, B., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32624 · Cited by 76
Self-citation
Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer
Ponz‐Sarvisé, M., Corbo, V., Tiriac, H., Engle, D. D., Frese, K. K., Oni, T. E., Hwang, C., Öhlund, D., Chio, I. I. C., Baker, L. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1398 · Cited by 65
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review
Santarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-639 · Cited by 65
Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities – Part 1
Das, D., Xie, L., Wang, J., Xu, X., Zhang, Z., Shi, J., Le, X., & Hong, J. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.056 · Cited by 65
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers
Kobayashi, Y., Chhoeu, C., Li, J., Price, K. S., Kiedrowski, L. A., Hutchins, J. L., Hardin, A. I., Wei, Z., Hong, F., Bahcall, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04451-4 · Cited by 56
The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine
Li, X., Li, M., Huang, M., Lin, Q., Fang, Q., Liu, J., Chen, X., Liu, L., Zhan, X., Shan, H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113064 · Cited by 57
The functions and molecular mechanisms of Tribbles homolog 3 (TRIB3) implicated in the pathophysiology of cancer
Arif, A., Alameri, A. A., Tariq, U. B., Ansari, S. A., Sakr, H. I., Qasim, M. T., Al-joborae, F. F. M., Ramírez‐Coronel, A. A., Jabbar, H. S., Gabr, G. A., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109581 · Cited by 66
KRAS: A Druggable Target in Colon Cancer Patients
Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 57
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 67
Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells
Booth, L. A., Roberts, J. L., Sander, C., Lalani, A. S., Kirkwood, J. M., Hancock, J. F., Poklepovic, A. S., & Dent, P. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1551747 · Cited by 49
Targeting KRAS mutant lung cancer: light at the end of the tunnel
Drosten, M., & Barbacid, M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13168 · Cited by 49
Self-citation
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Carvalho, P. D., Machado, A. L., Martins, F., Seruca, R., & Velho, S. (2019) · Cancers · doi:10.3390/cancers11122010 · Cited by 49
RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma
East, P., Kelly, G. P., Biswas, D., Marani, M., Hancock, D. C., Creasy, T. H., Sachsenmeier, K. F., Swanton, C., Downward, J., & Trécesson, S. D. C. (2022) · Nature Communications · doi:10.1038/s41467-022-33290-0 · Cited by 42
Down-regulation of A20 promotes immune escape of lung adenocarcinomas
Breitenecker, K., Homolya, M., Luca, A. C., Lang, V., Trenk, C., Petroczi, G., Mohrherr, J., Horvath, J., Moritsch, S., Haas, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc3911 · Cited by 42
Self-citation
Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression
Lin, C., Huang, Y., Cho, C.-F., Lin, Y., Lo, C.-C., Kuo, T.-T., Tseng, G., Cheng, W., Chang, W., Hsiao, T., et al. (2020) · Theranostics · doi:10.7150/thno.49425 · Cited by 38
Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study
Srisongkram, T., & Weerapreeyakul, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010669 · Cited by 37
FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma
Cooke, M., Kreider-Letterman, G., Baker, M. J., Zhang, S., Sullivan, N. T., Eruslanov, E. B., Abba, M. C., Goicoechea, S. M., García‐Mata, R., & Kazanietz, M. G. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109905 · Cited by 37
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018
Hu, Z., Li, M., Chen, Z., Zhan, C., Lin, Z., & Wang, Q. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.10.17 · Cited by 36
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症：英文版 · doi:10.1002/cac2.12377 · Cited by 38
EGF Induces Migration Independent of EMT or Invasion in A549 Lung Adenocarcinoma Cells
Schelch, K., Vogel, L., Schneller, A., Brankovic, J., Mohr, T. T., Mayer, R. L., Slany, A., Gerner, C., & Grusch, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.634371 · Cited by 36
KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
Karimi, N., & Moghaddam, S. J. (2023) · Cells · doi:10.3390/cells12050749 · Cited by 37
CRISPR-Cpf1-mediated genome editing and gene regulation in human cells
Li, T., Zhu, L., Xiao, B., Gong, Z., Liao, Q., & Guo, J. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.10.013 · Cited by 32
Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer
Kim, Y., Baek, D.-S., Lee, S., Park, D., Kang, H. N., Cho, B. C., & Kim, Y. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.09.005 · Cited by 31
Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy
Tian, D., Tang, J., Geng, X., Li, Q., Wang, F., Zhao, H., Narla, G., Yao, X., & Zhang, Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.08.008 · Cited by 32
Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
Cucurull, M., Notario, L., Sánchez‐Céspedes, M., Hierro, C., Estival, A., Carcereny, E., & Saigí, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.793121 · Cited by 33
Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway
Li, B., Yuan, Z., Jiang, J. F., & Rao, Y. (2018) · Bioscience Reports · doi:10.1042/bsr20181693 · Cited by 30
Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells
Plangger, A., Rath, B., Hochmair, M. J., Funovics, M. A., & Hamilton, G. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101230 · Cited by 24
Relationship between Lung Carcinogenesis and Chronic Inflammation in Rodents
Nakano‐Narusawa, Y., Yokohira, M., Yamakawa, K., Ye, J., Tanimoto, M., Wu, L., Mukai, Y., Imaida, K., & Matsuda, Y. (2021) · Cancers · doi:10.3390/cancers13122910 · Cited by 26
Targeting RAS in neuroblastoma: Is it possible?
Lin, L., Miao, L., Lin, H., Cheng, J., Li, M., Zhuo, Z., & He, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108054 · Cited by 24
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
McFall, T. B., Trogdon, M., Guizar, A. C., Langenheim, J. F., Sisk-Hackworth, L., & Stites, E. C. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00329-w · Cited by 25
CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor
Liu, B., Song, S., Setroikromo, R., Chen, S., Hu, W., Chen, D., van der Wekken, A. J., Melgert, B. N., Timens, W., van den Berg, A., et al. (2019) · Cancers · doi:10.3390/cancers11040455 · Cited by 22
Emerging RAS-directed therapies for cancer
Conroy, M. R., Cowzer, D., Kölch, W., & Duffy, A. G. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.07 · Cited by 23
MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer
Zhang, Y., Liang, S., Xiao, B., Hu, J., Pang, Y., Liu, Y., Yang, J., Ao, J., Wei, L., & Luo, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04709-9 · Cited by 23
A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer
Milton, C. K., Self, A. J., Clarke, P. A., Banerji, U., Piccioni, F., Root, D. E., & Whittaker, S. R. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1131 · Cited by 21
Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines
Kim, S., Kim, N., Kang, K., Kim, W., Won, J., & Cho, J. (2019) · Cells · doi:10.3390/cells8080878 · Cited by 20
Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity
Stangl, C., Post, J. B., van Roosmalen, M. J., Hami, N., Verlaan-Klink, I., Vos, H. R., van Es, R. M., Koudijs, M. J., Voest, E. E., Snippert, H. J. G., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0529 · Cited by 21
Regeneration-Associated Transitional State Cells in Pulmonary Fibrosis
Shen, M., Luo, Z., & Zhou, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126757 · Cited by 22
Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo
Kim, Y., Bismeijer, T., Zwart, W. T., Wessels, L. F. A., & Vis, D. J. (2019) · Nature Communications · doi:10.1038/s41467-019-13027-2 · Cited by 18
Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer
Wang, D., Cong, J., Fu, B., Zheng, X., Sun, R., Tian, Z., & Wei, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.043 · Cited by 19
Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors
Choi, J., Shin, J. H., Kim, T. K., Kim, K., Kim, J.-Y., Jeon, E., Park, J., Han, Y. D., Kim, K., Sim, T., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216904 · Cited by 19
Not the comfy chair! Cancer drugs that act against multiple active sites
Booth, L. A., Poklepovic, A. S., & Dent, P. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1691526 · Cited by 16
Inhibiting Pathways Predicted From a Steroid Hormone Gene Signature Yields Synergistic Antitumor Effects in NSCLC
Almotlak, A. A., Farooqui, M., & Siegfried, J. M. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.195 · Cited by 16
Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line
Tsukumo, Y., Naito, M., & Suzuki, T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229712 · Cited by 18
iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells
Sieber, B., Lu, F., Stribbling, S. M., Grieve, A. G., Ryan, A. J., & Freeman, M. (2022) · Journal of Cell Science · doi:10.1242/jcs.259949 · Cited by 16
Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers
Bagnyukova, T., Egleston, B. L., Pavlov, V. A., Serebriiskii, I. G., Golemis, E. A., & Borghaei, H. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0482 · Cited by 14
Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids
Gong, K., Guo, G., Beckley, N. A., Yang, X., Zhang, Y., Gerber, D. E., Minna, J. D., Burma, S., Zhao, D., Akbay, E. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27276-7 · Cited by 15
Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy
Almotlak, A. A., Farooqui, M., Soloff, A. C., Siegfried, J. M., & Stabile, L. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010081 · Cited by 14
Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer
Guo, D., Ye, L., Wu, W., Yu, X., & Jin, K. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023045 · Cited by 13
EGFR controls transcriptional and metabolic rewiring in KRASG12D colorectal cancer
Krauß, D., Moreno‐Viedma, V., Adachi-Fernandez, E., Fernandes, C. D. S., Genger, J., Fari, O., Blauensteiner, B., Kirchhofer, D., Bradaric, N., Gushchina, V., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00240-4 · Cited by 13
Self-citation
Synthetic Vulnerabilities in the KRAS Pathway
Román, M., Hwang, E. E., & Sweet-Cordero, A. (2022) · Cancers · doi:10.3390/cancers14122837 · Cited by 14
Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma
Neidler, S., Kruspig, B., Hewit, K. D., Monteverde, T., Gyurászová, K., Braun, A., Clark, W. A., James, D. T., Hedley, A., Nieswandt, B., et al. (2019) · Cancers · doi:10.3390/cancers11050600 · Cited by 12
Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer: insights from single-cell multi-omics
Hu, L., Wang, X., Song, Z., Chen, F., & Wu, B. Y. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00996-4 · Cited by 11
Nonnegative matrix factorization‐based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub‐consensuses of lung adenocarcinoma
Wang, H., Wang, X., Xu, L., Cao, H., & Zhang, J. (2021) · Cancer Medicine · doi:10.1002/cam4.4386 · Cited by 11
Kinase signalling adaptation supports dysfunctional mitochondria in disease
Skalka, G., Tsakovska, M., & Murphy, D. J. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1354682 · Cited by 12
Cx32 mediates norepinephrine‐promoted EGFR‐TKI resistance in a gap junction‐independent manner in non‐small‐cell lung cancer
Xie, J., Wang, X., Ge, H., Peng, F., Zheng, N., Wang, Q., & Tao, L. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28881 · Cited by 10
Structural and utational nalysis of ember-pecific STAT unctions
Erdogan, F., Qadree, A., Radu, T. B., Orlova, A., de Araujo, E. D., Israelian, J., Valent, P., Mustjoki, S. M., Herling, M., Moriggl, R., et al. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.130058 · Cited by 10
Self-citation
Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review
Juthani, R., & Manne, A. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1555963 · Cited by 12
Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras -Mutant Lung Cancers
Talwelkar, S. S., Nagaraj, A. S., Devlin, J. R., Hemmes, A., Potdar, S., Kiss, E. A., Saharinen, P., Salmenkivi, K., Mäyränpää, M. I., Wennerberg, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0573 · Cited by 7
Pulmonary Inflammation and KRAS Mutation in Lung Cancer
Keohavong, P., & Di, Y. P. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63046-1_5 · Cited by 9
Mechanisms of Cancer Resistance to Various Therapies
Batool, A., Rashid, W., Fatima, K., & Khan, S. U. (2024) · Springer eBooks · doi:10.1007/978-981-97-1666-1_2 · Cited by 9
A feedforward loop between STAT1 and YAP1 stimulates lipid biosynthesis, accelerates tumor growth, and promotes chemotherapy resistance in mutant KRAS colorectal cancer
Wang, S., Diao, S., Kim, H., Zou, J. Y., Li, K., & Koromilas, A. E. (2025) · Communications Biology · doi:10.1038/s42003-025-08740-2 · Cited by 8
PCM1: A Potential Prognostic Biomarker Correlated with Immune Infiltration in Lung Adenocarcinoma
Guo, Z., Liang, J., Zhang, X., Ai, Q., Xie, Z., Zhao, H., Wu, F., Tan, Z., Yin, W., & Ji, L. (2023) · Current Proteomics · doi:10.2174/0115701646270898231123065507 · Cited by 8
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
Piha-Paul, S. A., Tseng, C., Tran, H. T., Gao, M., Karp, D. D., Subbiah, V., Tsimberidou, A. M., Kawedia, J. D., Fu, S., Pant, S., et al. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04545-4 · Cited by 7
If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer
Köhler, J., & Janne, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063025 · Cited by 7
Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition
Matsubara, S., Tsukasa, K., Kuwahata, T., & Takao, S. (2020) · Human Cell · doi:10.1007/s13577-020-00416-9 · Cited by 8
Regulatory function of peroxiredoxin I on 4‑(methylnitrosamino)‑1‑(3‑pyridyl)‑1‑butanone‑induced lung cancer development (Review)
Sun, H., Ren, C., Gong, Y.-X., XIE, D.-P., & Kwon, T. (2021) · Oncology Letters · doi:10.3892/ol.2021.12726 · Cited by 7
D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC
Sun, X., Dai, Y., He, J., Li, H., Yang, X., Dong, W., Xie, X., Wang, M., Xu, Y., & Lv, L. (2023) · Oncogene · doi:10.1038/s41388-023-02856-7 · Cited by 6
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Moll, H. P., Mohrherr, J., Breitenecker, K., Haber, M., Voronin, V., & Casanova, E. (2019) · Journal of Visualized Experiments · doi:10.3791/58101 · Cited by 7
Self-citation
The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein–protein interaction in glioblastoma
Neirinckx, V., Hau, A., Schuster, A. M., Fritah, S., Tiemann, K., Klein, E., Nazarov, P. V., Matagne, A., Szpakowska, M., Meyrath, M., et al. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz024 · Cited by 6
Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond
Huang, R., Gong, X., Du, J., Xu, G., Qian, J., Liao, G., Lin, Y., Pan, M., Zheng, B., Yuan, W., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704347 · Cited by 6
Ganoderma microsporum immunomodulatory protein combined with KRASG12C inhibitor impedes intracellular AKT/ERK network to suppress lung cancer cells with KRAS mutation
Hua, W.-J., Hwang, W., Yeh, H. H., Lin, Z., Hsu, W.-H., & Lin, T. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129291 · Cited by 5
Primary Prevention and Interception Studies in RAS-Mutated Tumor Models Employing Small Molecules or Vaccines
Dragnev, K. H., Lubet, R. A., Miller, M. S., Sei, S., Fox, J. T., & You, M. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-23-0027 · Cited by 3
Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma
Luca, A. C., Kurnaeva, M., John, D. K., Machtinger, M., Vollmer, N. H. J., Mödl, B., Hannich, J. T., Eckhard, M., Lam, H. S., Musiejovsky, L., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217733 · Cited by 3
Self-citation
Cancer modeling in colorectal organoids reveals intrinsic differences between oncogenic RAS and BRAF variantsPreprint
Post, J. B., Hami, N., Lohuis, J. O., van de Ven, M., de Korte‐Grimmerink, R., Stangl, C., Stelloo, E., Verlaan-Klink, I., van Rheenen, J., & Snippert, H. J. G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/860122 · Cited by 3
A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancerPreprint
Kaushik, S., Haderk, F., Zhao, X., Hu, H., Shah, K. N., Jang, G. Μ., Olivas, V. R., Nanjo, S., Jascur, J., Masto, V. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.02.185173 · Cited by 3
The role of miRNA-571 and miRNA-559 in lung cancer by affecting the expression of genes associated with the ErbB signaling pathway
Jasim, S. A., Omear, H. A., & AL-Marzoqi, A. H. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101436 · Cited by 2

Authors: Moll, H. P., Pranz, K., Musteanu, M., Grabner, B., Hruschka, N., Mohrherr, J., Aigner, P., Stiedl, P., Brcic, L., Laszlo, V., Schramek, D., Moriggl, R., Eferl, R., Moldvay, J., Dezso, K., Lopez-Casas, P. P., Stoiber, D., Hidalgo, M., Penninger, J., Sibilia, M., Győrffy, B., Barbacid, M., Dome, B., Popper, H., & Casanova, E.
Affiliations: Comprehensive Cancer Center Vienna (AT)
Ludwig Boltzmann Institute for Cancer Research (AT)
Spanish National Cancer Research Centre, E-28029 Madrid, Spain.
Institute of Pathology, Medical University of Graz, AT-8036 Graz, Austria.
Division of Thoracic Surgery, Department of Surgery and CCC, Medical University of Vienna, AT-1090 Vienna, Austria.
Institute of Molecular Biotechnology (AT)
University of Veterinary Medicine Vienna (AT)
Semmelweis University (HU)
First Department of Pathology and Experimental Cancer Research, Semmelweis University, HU-1122 Budapest, Hungary.
Spanish National Cancer Research Centre (ES)
Medical University of Graz (AT)
Corresponding author: Casanova, Emilio
ORCID: Moll, Herwig P.
Pranz, Klemens
Musteanu, Monica
Brcic, Luka
Laszlo, Viktoria
Schramek, Daniel
Moriggl, Richard
Eferl, Robert
Moldvay, Judit
Lopez-Casas, Pedro P.
Stoiber, Dagmar
Hidalgo, Manuel
Penninger, Josef
Sibilia, Maria
Győrffy, Balázs
Barbacid, Mariano
Dome, Balázs
Popper, Helmut
Casanova, Emilio
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2018-06-20
Volume: 10
Issue: 446
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.aao2301
PMC: PMC7610658
OpenAlex: W2808999647
Cited by: 125
References: 51
Citations by year: 2026: 4 · 2025: 8 · 2024: 8 · 2023: 11 · 2022: 18 · 2021: 21 · 2020: 22 · 2019: 23 · 2018: 9
FWCI: 14.32
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
PubMed Central (acceptedVersion)
Semmelweis University Repository (Semmelweis University) (submittedVersion)
Funders: Austrian Science Fund (FWF-P25599-B19, SFB-F4707, SFB-F06105)
Fellinger Krebsforschungsverein
National Research, Development and Innovation Office, Hungary (NVKP_16-1-2016-0037)
Hungarian NRDI Office (K109626, K108465, KNN121510, SNN114490)
Hungarian Academy of Science
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: afatinib, KRAS mutation, lung adenocarcinoma, lung carcinogenesis, ErbB signaling, pan-ErbB inhibitor, EGFR, HER2, HER3, ErbB4, tyrosine kinase inhibitors
MeSH terms: Erlotinib Hydrochloride, Gefitinib, Adenocarcinoma of Lung, Afatinib, Humans, Lung Neoplasms, Mutation, Signal Transduction, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Cell Line, Tumor, Cell Proliferation, Carcinogenesis, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Afatinib restrains K-RAS–driven lung tumorigenesis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks